ALPMF News and Press, Astellas Pharma Inc From 08/01/22

Astellas Pharma press release ( OTCPK:ALPMF ): Q1 GAAP EPS of ¥25.12. Revenue of ¥381.79B (+17.1% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥25.12, revenue of ¥381.79B

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Astellas Pharma Inc. 2022 Q1 - Results - Earnings Call Presentation

Mitobridge, a subsidiary of Japan's Astellas Pharma ( OTCPK:ALPMY ), has inked a licensing agreement with Generian Pharmaceuticals to develop small molecules for undruggable therapeutic targets. The collaboration will lean on privately-held Generian's proprietary drug-disc...

Sutro Biopharma (NASDAQ:STRO) stocks surged 50.6% after-hours on Monday after the firm entered into worldwide, strategic collaboration and licensing pact with Astellas Pharma (OTCPK:ALPMF) focused on the discovery and development of novel immunostimulatory antibody-drug conjuga...

Shares of Xencor have fallen by 46% since my 2019 update. I initially liked this one for "picks and shovels" aspect of the story. XmAb technology is being utilized by a variety of big pharmaceutical companies, with focus on bispecific antibodies and engineered cytokines. Xencor is...

Generic drugmaker Amphastar Pharmaceuticals (NASDAQ:AMPH) announced on Monday that the FDA approved its Abbreviated New Drug Application ("ANDA") for Regadenoson, a bioequivalent and therapeutically equivalent to Lexiscan developed by Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY). Regadenoson i...

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...

TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low. The stock is drastically undervalued based on only fraction of the pipeline and multiples of upside. Multiple insider purchases support the bull case and timing. For further details s...

Twist Bioscience (NASDAQ:TWST) said it signed a collaboration and exclusive option license agreement with Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) for antibodies to reduce tumor microenvironment-mediated immunosuppression. Under the agreement, the companies will jointly conduct resear...

Astellas Pharma, Inc. (ALPMF) Q4 2022 Results Conference Call April 27, 2022 01:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President and CEO Bernie Zeiher - Chief Medical Officer Yukio Matsui - Chief Commercial Officer Minoru Kikuok...